{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:04:20Z","timestamp":1790697860672,"version":"4.1.0"},"reference-count":46,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    To evaluate the impact of spectral-domain optical coherence tomography (SD-OCT) evaluation for maculopathy in eyes with retinoblastoma treated with external beam radiation coupled with targeted intravitreal antivascular endothelial growth factor (bevacizumab) on the treatment of radiation retinopathy.\n                    <jats:bold>Methods:<\/jats:bold>\n                    This is an institutional review board\u2013approved, retrospective analysis of a consecutive case series of eyes with post\u2013external beam radiation regressed retinoblastoma developing SD-OCT\u2013confirmed retinopathy and documented visual decline. All patients were treated with external beam radiotherapy (40-50 Gy in 1.8-2.0 Gy fractions) prior to inclusion. Intravitreal bevacizumab 1.25 mg was injected in all eyes that met the inclusion criteria. All patients were treated with a primary treat-and-adjust schedule focused initially on a 6-week interval.\n                    <jats:bold>Results:<\/jats:bold>\n                    Nineteen subjects (11 male, 8 female) were included, with a mean follow-up of 40 months (range, 30-66 months). A total of 30 eyes met the inclusion criteria. After treatment, the mean SD-OCT central subfield foveal thickness of the entire cohort decreased from 511 \u03bcm at baseline to 389 \u03bcm by month 2, and 263 \u03bcm by year 2. Mean cohort intravitreal injections of bevacizumab totaled 8.2 during the first year, 7.6 during the third year, and 5.9 during the fifth year.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    This study offers new medical evidence suggesting that early diagnosis and antivascular endothelial growth factor therapy may improve visual outcomes in pediatric radiation retinopathy. Intravitreal bevacizumab improved visual acuity and anatomy in pediatric eyes with stable retinoblastoma and radiation maculopathy.\n                  <\/jats:p>","DOI":"10.1177\/24741264261438443","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T02:12:05Z","timestamp":1776305525000},"page":"1003-1009","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Pediatric Radiation Retinopathy: Impact of Early Diagnosis and Targeted Treatment"],"prefix":"10.1177","volume":"10","author":[{"given":"Victor M.","family":"Villegas","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico"},{"name":"Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA"},{"name":"Department of Surgery, Ponce Health Sciences University, Ponce, Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6340-9771","authenticated-orcid":false,"given":"Amaris D.","family":"Rosado","sequence":"additional","affiliation":[{"name":"University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Gold","sequence":"additional","affiliation":[{"name":"Murray Ocular Oncology and Retina, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"El Hamichi","sequence":"additional","affiliation":[{"name":"Murray Ocular Oncology and Retina, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audina M.","family":"Berrocal","sequence":"additional","affiliation":[{"name":"Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azeema","family":"Latiff","sequence":"additional","affiliation":[{"name":"Murray Ocular Oncology and Retina, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy G.","family":"Murray","sequence":"additional","affiliation":[{"name":"Murray Ocular Oncology and Retina, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.04.017"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.031"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2018.07.002"},{"key":"e_1_3_2_5_2","article-title":"Ranibizumab for the prevention of radiation complications in patients treated with proton beam irradiation for choroidal melanoma","volume":"114","author":"Kim IK","year":"2016","unstructured":"Kim IK, Lane AM, Jain P, Awh C, Gragoudas ES. Ranibizumab for the prevention of radiation complications in patients treated with proton beam irradiation for choroidal melanoma. Trans Am Ophthalmol Soc. 2016;114:T2.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.08.039"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/517032"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.08.026"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-018-0123-1"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.1991.39"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijtm3010011"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells14040298"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000479558"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.111"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.02.005"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2012.249"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)90347-6"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-302808"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.01.025"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2013.4422"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_721_20"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1996.01100140548005"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/iae.0000000000001874"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e3283386687"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2004.052159"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.12.034"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31814b1b75"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-22324"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(92)31832-9"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.2147\/opth.s34949"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.386"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-016-3541-5"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.124.10.1428"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5000670"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.02.009"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2016.05.26"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1159\/000452163"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.2147\/opth.s47684"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_200_21"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.12.025"},{"key":"e_1_3_2_41_2","first-page":"29","volume-title":"Cesk Slov Oftalmol","author":"Autrata R","year":"2012","unstructured":"Autrata R, Senkov\u00e1 K, Holousov\u00e1 M, Krejc\u00edrov\u00e1 I, Dolezel Z, Borek I. Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II\u2014four years results. Cesk Slov Oftalmol. 2012;68(1):29-36. Pr\u00ednos intravitre\u00e1ln\u00ed aplikace anti-VEGF prepar\u00e1t\u016f v l\u00e9cbe prahov\u00e9ho stadia ROP 3+ v z\u00f3ne I-II: v\u00fdsledky ctyrlet\u00e9 studie."},{"key":"e_1_3_2_42_2","unstructured":"Board PPTE. PDQ retinoblastoma treatment. National Cancer Institute. 2025. Updated April 3 2025. Accessed October 24 2025. https:\/\/www.cancer.gov\/types\/retinoblastoma\/hp\/retinoblastoma-treatment-pdq"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.3129\/i10-111"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.117.5.609"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100981"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/iae.0000000000001414"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20190301-03"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264261438443","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264261438443","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264261438443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:24:18Z","timestamp":1790695458000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264261438443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1177\/24741264261438443"],"URL":"https:\/\/doi.org\/10.1177\/24741264261438443","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]}}}